title: Effectiveness of botulinum toxin B in the treatment of drooling.
abstract: The aim of this audit was to assess the effectiveness of botulinum toxin B (NeuroBloc(®), Eisai Ltd.) in the treatment of drooling. Over a period of 18 months patients treated with NeuroBloc(®) botulinum toxin (BTX) for serious drooling (drooling score more than 7) were invited to complete a questionnaire on their experience of drooling and the impact of treatment. A total of 170 questionnaires were given to consecutive patients or carers and 145 (85%) responded. Of these, 128 (88%) reported that symptoms had improved by 6/10 or more on a visual analogue scale (VAS), and 54 (37%) reported compete resolution of drooling (10/10 VAS). A total of 139 (96%) would recommend the treatment to others.
authors: Maxillofacial Department, Kings College Hospital, Denmark Hill, London SE5 9RS, United Kingdom. Electronic address: kgeorge1@nhs.net.
authors: Katherine S
authors: KS
authors: George
authors: Hamid
authors: H
authors: Kiani
authors: Helen
authors: H
authors: Witherow
mesh_terms: D065087:Acetylcholine Release Inhibitors / Q000627:therapeutic use*; D000203:Activities of Daily Living; D001294:Attitude to Health; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D019230:Dental Audit; D006801:Humans; D007398:Interpersonal Relations; D017060:Patient Satisfaction; D036301:Qualitative Research; D011788:Quality of Life; D012649:Self Concept; D012798:Sialorrhea / Q000188:drug therapy* / Q000523:psychology; D064232:Visual Analog Scale
chemical_list: D065087:Acetylcholine Release Inhibitors; C096323:rimabotulinumtoxinB; D019274:Botulinum Toxins, Type A
keywords: Botulinum toxin; Drooling; Sialorrhoea